ADENOSINE PROMOTES NEUTROPHIL CHEMOTAXIS

By F. ROBERTA ROSE, ROCHELLE HIRSCHHORN, GERALD WEISSMANN, and BRUCE N. CRONSTEIN

From the Division of Rheumatology, Department of Medicine, New York University Medical Center, New York, New York 10016

Adenosine modulates the function of a wide variety of cells by engaging specific receptors on the cell surface. We have recently demonstrated the presence of adenosine receptors on human neutrophils and shown that engagement of adenosine receptors on neutrophils inhibits superoxide and hydrogen peroxide production, adherence to endothelial cell monolayers, and killing of cultured endothelial cells by stimulated neutrophils (1-4). We and subsequently others have shown that adenosine inhibits neutrophil function by engaging a specific subset of adenosine receptors, A2 receptors (2, 5-7). There are two types of cell surface adenosine receptors, A1 and A2, which are differentiated by their affinity for adenosine, the order of potency of adenosine analogues and, in many studies, opposing effects on cellular cAMP metabolism (8-10). Methylxanthines are competitive antagonists at both A1 and A2 receptors.

We now report the surprising observation that, in marked contrast to the inhibition of neutrophil functions that we have previously described, adenosine and its analogues promote neutrophil chemotaxis without affecting chemokinesis. Moreover, adenosine enhances chemotaxis by engaging A2 receptors as indicated by the order of agonist potency. The paradoxical effect of adenosine A2 receptor engagement on stimulated neutrophil function, inhibition of superoxide anion generation but promotion of chemotaxis, suggests that engagement of chemotactant receptors stimulates movement and the respiratory burst by divergent pathways.

Materials and Methods

Materials. Adenosine, 2-chloroadenosine, Weigert's hematoxylin stain, and human serum albumin were obtained from Sigma Chemical Co. (St. Louis, MO). FMLP was obtained from Vega Biochemicals (Tuscon, AZ). N<sup>6</sup>-(L)-phenylisopropyladenosine (PIA) was obtained from Boehringer Mannheim Biochemicals (Indianapolis, IN). 5'-N-ethylcarboxamidoadenosine (NECA) and 8-p-sulfophenyltheophylline (8-PST) were obtained from Research Biochemicals, Inc. (Wayland, MA). Agarose was obtained from Bio-Rad Laboratories (Rockville Center, NY). Zymosan was obtained from ICN Biomedicals, Inc.

This work was supported by a generous grant from the American Lung Association to Dr. Cronstein and grants AI-10343, AI-17365, AR-11949, and HL-19721 from the National Institutes of Health. Dr. Cronstein is the recipient of Clinical Investigator Award K11AR01490 from the National Institutes of Health. Address correspondence to B. N. Cronstein, Division of Rheumatology, Dept. of Medicine, New York University Medical Center, 550 First Avenue, New York, NY 10016.

Abbreviations used in this paper: EC<sub>50</sub>, concentration at which 50% effect occurs; NECA, 5'-N-ethylcarboxamidoadenosine; PIA, N<sup>6</sup>-L-phenylisopropyladenosine; 8-PST, 8-p-sulfophenyltheophylline.
Nitrocellulose filters were obtained from Millipore Corp. (Bedford, MA). Tissue culture plates were manufactured by Becton Dickinson Labware (Lincoln Park, NJ). Medium RPMI 1640 (10X) and sterile NaHCO₃ solution (7.5%) were obtained from Gibco Laboratories (Grand Island, NY).

Isolation of Neutrophils. Human neutrophils were isolated from heparinized whole blood by centrifugation through Ficoll-Hypaque and sedimentation through dextran (6% wt/vol) followed by hypotonic lysis of erythrocytes. This procedure allows study of populations of cells that are 98 ± 2% neutrophils with few contaminating erythrocytes or platelets (11). Neutrophils were suspended for all of the experiments reported here in PBS containing magnesium (0.5 mM) and calcium (0.9 mM).

Generation of Zymosan-activated Plasma (ZAP). Heparinized plasma was incubated with zymosan (1 mg/ml) for 30 min at 37°C, centrifuged at 1,000 g for 10 min, and the supernatant was collected and kept on ice until use. For use in chemotactic assays the ZAP was diluted 1:10 with incubation buffer (12).

Chemotaxis Assays. Chemotaxis through a filter was measured using the modified Boyden chamber technique of Zigmond and Hirsch (13) as modified by Axelsson et al. (14). Neutrophils (6 X 10⁵) were preincubated at 37°C for 10 min with or without adenosine, adenosine analogues, and/or 8-PST and were then layered onto nitrocellulose filters (3-μm pore size) overlying chemotactic stimuli (e.g., ZAP, 10%) in an apparatus described by Axelsson et al. (14; a gift from Pharmacia AB, Uppsala, Sweden). The cells were then incubated for 35 min at 37°C in a 5% CO₂ atmosphere, after which the filters were removed, stained with hematoxylin, and mounted on microscopeslides. The extent of chemotaxis was determined by the leading front technique. Before analysis the original codings on the slides were covered over and the slides coded so that the reader was unaware of the condition being examined. Each condition was tested in triplicate or quadruplicate and leading fronts were measured on three sites per filter. Random migration of cells towards buffer alone, chemokinesis, was subtracted from the distance travelled by cells towards the chemotactic stimulus, chemotaxis. Chemotaxis by cells incubated with adenosine or its analogues is expressed as percent of control chemotaxis. Data were then fit to a curve by means of the ALLFIT computer program on an Apple IIe desktop computer (15; Dr. Carl Johnson, University of Cincinnati College of Medicine, Cincinnati, OH).

Chemotaxis under agarose was measured by a modification of the method of Nelson et al. (16). Agarose (2% wt/vol, final) was dissolved in water and then mixed with an equal volume of a solution containing RPMI 1640 (2X) and human serum albumin (1.5% wt/vol) adjusted to a pH of 7.4 with NaHCO₃ solution (7.5%, wt/vol). The final solution was layered onto tissue culture plates and permitted to solidify. A series of three wells 3 mm apart were cut into the agarose using a template. An aliquot (10 μl) of a neutrophil suspension (3 X 10⁶/ml) was placed in the center well and either buffer or a solution of FMLP was placed in the flanking wells. In preliminary experiments we determined that the optimal concentration of FMLP for chemotaxis was 10⁻⁷ M. Each condition was studied in triplicate. The plates were then incubated for 3–4 h at 37°C in a 5% CO₂ atmosphere, then fixed with a solution of glutaraldehyde (2%) and, after removal of the agarose, the cells were stained with Weigert’s hematoxylin for 2 min. The plates were studied using an inverted microscope with the image projected onto a screen at a magnification of ×200. Chemotaxis was determined by quantitating the number of cells contained in an area measuring 25 X 25 mm at varying distances from the origin along the shortest line connecting the wells containing cells and chemoattractant. Each box was assigned a relative value (ranging from 1–6), depending upon its distance from the well containing the cells. Chemokinetics was determined similarly in the direction of the well containing buffer. A chemotactic index was calculated by multiplying the cells in each box by the appropriate weighting figure, calculating the sum of the weighted number of cells, and then subtracting the sum calculated for chemokinetics from the sum derived for chemotaxis. The data are expressed as a percentage of control.

Chemokinesis Determinations. Neutrophil chemokinesis was assessed using the checkerboard analysis technique of Zigmond and Hirsch (13). Buffer or varying concentrations...
Adenosine Promotes Neutrophil Chemotaxis.

In our initial experiments we studied the effect of varying concentrations of adenosine on neutrophil chemotaxis stimulated by ZAP. We found that concentrations of adenosine ranging from 1 to 10,000 nM enhanced chemotaxis in a dose-dependent manner (Fig. 1).

Adenosine Enhances Chemotaxis by Engaging A2 Receptors. To determine whether adenosine promotes chemotaxis by engaging an A1 or an A2 receptor, we next examined the effects of NECA, the most potent A2 agonist, and PIA, a potent A1 agonist, on neutrophil chemotaxis. NECA and PIA both enhanced chemotaxis in a dose-dependent manner (Fig. 2) with similar maximal enhancement. However, NECA was a significantly more potent promoter of chemotaxis than either PIA or adenosine (p < 0.01, Fig. 2, Table 1). Adenosine did not differ significantly from PIA with respect to promotion of chemotaxis. Thus, the
TABLE I

Adenosine Enhances Chemotaxis by Engaging an A2 Receptor

| Adenosine analogue | EC<sub>50</sub> nM | Maximal enhancement % |
|--------------------|-----------------|-----------------------|
| NECA               | 0.34 ± 0.26     | 72 ± 6                |
| PIA                | 25.00 ± 18.00   | 69 ± 11               |
| Adenosine          | 59.00 ± 46.00   | 60 ± 7                |

Mean chemotaxis, as a percentage of control, was calculated at each concentration used and the data were fit to a curve by means of the ALLFIT program. The EC<sub>50</sub> (concentration of ligand required to produce 50% of maximal enhancement of chemotaxis) and maximal enhancement figures were calculated from the dose-response curves by means of the computer program. The dose-response curves are shown in Figs. 1 and 2 and represent the results of three to seven separate determinations using the cells from different donors.

ROSE ET AL.

FIGURE 3. 8-PST reverses NECA-mediated enhancement of chemotaxis. Neutrophils (6 x 10<sup>5</sup>) were incubated for 10 min with buffer, NECA at the indicated concentrations and/or 8-PST (10 μM). Chemotaxis to ZAP (10%) was quantitated as described in Materials and Methods. Each condition was tested in triplicate and leading fronts were determined on three sites per filter. Chemotaxis is expressed as percent control chemotaxis. These results are from a single experiment representative of three experiments. The chemotactic index of control cells in this experiment was 51 ± 3 μm.

order of potency of the adenosine analogues (NECA > PIA ≥ adenosine) is identical to that we had previously found for inhibition of superoxide anion generation and is characteristic of an adenosine A<sub>2</sub> receptor (2).

8-PST Abolishes NECAs Enhancement of Chemotaxis to ZAP. To provide further evidence that adenosine and its analogues act at specific adenosine receptors to enhance chemotaxis, we determined whether 8-PST, a potent adenosine receptor antagonist, could reverse promotion of chemotaxis by adenosine receptor agonists. Alone, 8-PST (10 μM) affected neither chemotaxis (98 ± 4% of control, n = 4) nor chemokinesis (99 ± 5% of control, n = 3). However, 8-PST (10 μM) completely abolished NECA-mediated (1–100 nM) enhancement of chemotaxis from a maximal enhancement of 71 ± 8% (concentration of NECA, 100 nM) to 1 ± 2% enhancement (n = 3, Fig. 3). These results are consistent with the hypothesis that NECA engages an adenosine receptor to enhance chemotaxis.

Adenosine Analogues Do Not Affect Chemokinesis. Increased random movement in the presence of adenosine and its analogues might account for the apparent promotion of chemotaxis. We therefore performed a checkerboard analysis of the effects of NECA on random migration of neutrophils (chemokinesis). NECA alone did not promote random migration of neutrophils nor did it act as a chemotactic agent (Table II). Similar results were obtained when the adenosine
ADENOSINE PROMOTES NEUTROPHIL CHEMOTAXIS

TABLE II

NECA Does Not Promote Chemokinesis

| NECA above filter | NECA (µM) below filter | Control (10% ZAP) |
|-------------------|------------------------|-------------------|
| µM                | µm                     |                   |
| 0.0               | 22 ± 2                 | 20 ± 1            | 114 ± 4 |
| 0.01              | 23 ± 2                 | 23 ± 2            | 18 ± 1  |
| 0.1               | 19 ± 4                 | 23 ± 2            | 21 ± 1  |
| 1.0               | 21 ± 1                 | 23 ± 1            | 18 ± 1  |
| 10.0              | 23 ± 2                 | 23 ± 1            | 21 ± 1  |

NECA, at the indicated concentrations, was added to buffer above (with PMNs) and/or below nitrocellulose filters in a modified Boyden chamber. The data are presented as the mean movement through the filter (± SEM) in micrometers and represent the measurement of three sites per filter in two separate filters.

TABLE III

NECA Promotes Chemotaxis to FMLP When Studied Using Chemotaxis under Agarose

| Concentration of NECA | Control chemotaxis |
|-----------------------|--------------------|
| M                     | Exp. 1             | Exp. 2             |
| 10⁻⁴                  | 182                | 496                |
| 10⁻³                  | 165                | 526                |
| 10⁻²                  | 175                | 420                |
| 10⁻¹                  | 157                | 388                |
| 10⁻⁰                  | 157                | 578                |
| 10⁰                   | ND                 | 245                |

Neutrophils (3 × 10⁵) were placed in wells cut into the agarose in the presence of buffer or NECA at the indicated concentrations. Chemotaxis to FMLP (10⁻⁷ M) was determined as described in Materials and Methods. These results represent the means of triplicate determinations. Mean control chemotactic index was 408 and 132 in Exp. 1 and 2, respectively.

The Adenosine Analogue NECA Also Promotes Neutrophil Chemotaxis under Agarose. To confirm that engagement of adenosine receptors promotes chemotaxis we studied chemotaxis using a second method, chemotaxis under agarose, and a second chemotactic agent, FMLP. We found that NECA also promoted chemotaxis to FMLP when studied using this technique (Table III). Using this technique we also did not find any effect of NECA on chemokinesis (data not shown).

Discussion

We and others have previously demonstrated that adenosine and its analogues, by engaging a specific receptor on human neutrophils, inhibit a variety of neutrophil functions (1–4, 8–10). Therefore we were surprised when we observed that adenosine promotes rather than inhibits chemotaxis yet does not affect chemokinesis. Even more surprising is the observation that adenosine...
promotes chemotaxis by engaging $A_2$ adenosine receptors; the same receptors that, when engaged, inhibit superoxide anion generation. No other agent, to our knowledge, promotes chemotaxis without affecting chemokinesis yet inhibits superoxide anion generation.

Adenosine is an autocoid that modulates the behavior of a wide range of mammalian cell types. Indeed, adenosine or its analogues have previously been reported to promote sperm motility by a mechanism that may involve cAMP but is probably not mediated by engagement of adenosine receptors (18–19). Moreover, adenosine is chemotactic for porcine endothelial cells, again by a mechanism that is not completely understood (20). The results of the studies reported here and previously suggest that adenosine and its analogues possess the general property of promoting motility. However, adenosine has been demonstrated to promote motility by a receptor-mediated mechanism only in the neutrophil.

Our demonstration that adenosine and its analogues promote chemotaxis conflicts with previous reports on the effect of adenosine on chemotaxis. Nishida et al. (21) found that concentrations of adenosine and PIA (200–2,000 μM) much higher than those used here (1 pM to 100 μM) did not affect neutrophil chemotaxis. Garcia-Castro et al. (22) were also unable to demonstrate that adenosine affected chemotaxis of rabbit neutrophils directly. The discrepancy between our results and those reported by Nishida et al. and Garcia-Castro et al. probably arises from the different methods used to measure chemotaxis by these groups and us. We have used the leading front technique to assess chemotaxis through a nitrocellulose filter whereas Nishida et al. (21) and Garcia-Castro et al. (22) have quantitated the number of cells adherent to the underside of the nitrocellulose filter. This latter method would underestimate chemotaxis if the migrating neutrophils did not remain adherent to the filter. We have previously reported that an adenosine receptor agonist, 2-chloroadenosine, inhibits adherence of stimulated neutrophils to cultured endothelial cells (3). Diminished adherence of neutrophils to the filters due to adenosine or its analogues could also contribute to the inability of previous investigators to detect adenosine-enhanced chemotaxis by quantitating the number of adherent cells on the underside of the filter. Measurement of chemotaxis by determining the leading front of neutrophils within the filter after a shorter incubation period avoids underestimation of chemotaxis due to nonadherence of neutrophils. Furthermore, we confirmed our findings by use of a second technique, chemotaxis under agarose. Finally, we found that adenosine and its analogues promoted chemotaxis to two different stimuli.

The mechanism by which adenosine receptor engagement inhibits superoxide anion generation and adherence to endothelial cells but enhances chemotaxis remains obscure. We have examined several mechanisms by which adenosine receptor engagement could alter signal transduction in the neutrophil. Adenosine does not interfere with stimulated calcium movements in neutrophils. Engagement of adenosine $A_2$ receptors induces an increase in cAMP content in several cell types (5–7). We and others have been able to demonstrate that both adenosine and NECA induce a rapidly reversible (5 min) increase in neutrophil cAMP content but only in the presence of a phosphodiesterase inhibitor (9, 23). The chemoattractant FMLP also elicits increased intracellular cAMP concentrations
in neutrophils. The increment in neutrophil cAMP concentration that follows stimulation by FMLP is enhanced by NECA in the presence of the phosphodiesterase inhibitor (23). However the role of cAMP in neutrophil motility is only poorly understood, with some groups reporting that agents that increase cellular cAMP content promote chemotaxis while others report the opposite (24–30). Adenosine receptor engagement could lead to alterations in stimulated phospholipid metabolism, activation of intracellular kinases, tyrosinylation of the cytoskeleton or other triggering mechanisms for stimulus response coupling in the neutrophil.

While adenosine is released from many different types of cells or tissue it is released in greater quantity from damaged cells (1, 30–32). We have found that adenosine, at concentrations similar to those found in the circulation (33), possesses the unique ability to promote neutrophil chemotaxis while inhibiting neutrophils from releasing potentially toxic oxygen metabolites into the extracellular milieu. Thus, adenosine may promote migration of neutrophils to sites of infection or tissue necrosis yet prevent the migrating neutrophils from damaging healthy tissues en route.

Summary

We have previously (1–4) demonstrated that adenosine, by engaging specific receptors on the surface of neutrophils, inhibits generation of toxic oxygen metabolites by activated neutrophils and prevents these activated neutrophils from injuring endothelial cells. We now report the surprising observation that engagement of these same neutrophil adenosine receptors promotes chemotaxis to C5 fragments (as zymosan-activated plasma [ZAP]) or to the bacterial chemotactant FMLP. When chemotaxis was studied in a modified Boyden chamber, physiologic concentrations of adenosine promoted chemotaxis by as much as 60%. Adenosine receptor analogues, 5′N-ethylcarboxamidoadenosine (NECA) and N6-phenylisopropyladenosine (PIA), also promoted chemotaxis; the order of agonist potency was consistent with that of an A2 adenosine receptor (NECA > PIA ≥ adenosine). A potent antagonist at adenosine receptors, 8-p-sulfophenyltheophylline (10 μM), completely reversed NECA enhancement of chemotaxis but did not affect chemotaxis by itself. Neither NECA nor 2-chloroadenosine, a nonselective adenosine receptor agonist, alone was chemotactic or chemokinetic by checkerboard analysis. NECA also promoted chemotaxis quantitated by a different technique, chemotaxis under agarose, to the surrogate bacterial chemoattractant FMLP. These data suggest that engagement of adenosine A2 receptors uniquely modulates neutrophil function so as to promote migration of neutrophils to sites of tissue damage while preventing the neutrophils from injuring healthy tissues en route.

The authors wish to thank Ms. Catherine Pugliese and Mr. Herns Charles for their technical assistance in performing this study.

Received for publication 25 September 1987 and in revised form 30 November 1987.
References

1. Cronstein, B. N., S. B. Kramer, G. Weissmann, and R. Hirschhorn. 1983. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J. Exp. Med. 158:1160.

2. Cronstein, B. N., E. D. Rosenstein, S. B. Kramer, G. Weissmann, and R. Hirschhorn. 1985. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J. Immunol. 135:1366.

3. Cronstein, B. N., R. I. Levin, J. Belanoff, G. Weissmann, and R. Hirschhorn. 1986. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin. Invest. 78:760.

4. Cronstein, B. N., S. M. Kubersky, G. Weissmann, and R. Hirschhorn. 1987. Engagement of adenosine receptors inhibits hydrogen peroxide (H2O2) release by activated neutrophils. Clin. Immunol. Immunopathol. 42:76.

5. Roberts, P. A., A. C. Newby, M. B. Hallett, and A. K. Campbell. 1985. Inhibition by adenosine of reactive oxygen metabolite production by human polymorphonuclear leucocytes. Biochem. J. 227:669.

6. Iannone, M. A., R. Reynolds-Vaughn, G. Wolberg, and T. P. Zimmerman. 1985. Human neutrophils possess adenosine A2 receptors. Fed. Proc. 44:580.

7. Schrier, D. J., and K. M. Imre. The effects of adenosine agonists on human neutrophil function. J. Immunol. 137:3284.

8. Van Calker, D., M. Muller, and B. Hamprecht. 1979. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33:999.

9. Londos, C., M. F. D. Cooper, and J. Wolff. 1980. Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. USA. 77:2551.

10. Daly, J. W., R. F. Bruns, and S. H. Snyder. 1981. Adenosine receptors in the central nervous system: relationship to the central actions of methylxanthines. Life Sci. 28:2083.

11. Boyum, A. 1968. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by centrifugation and sedimentation at 1 × g. Scand. J. Clin. Lab. Invest. 21:77.

12. Goldstein, I. M., D. Roos, H. B. Kaplan, and G. Weissmann. 1975. Complement and immunoglobulins stimulate superoxide production independent of phagocytosis. J. Clin. Invest. 56:1155.

13. Zigmond, S. H., and J. G. Hirsch. 1973. Leukocyte locomotion and chemotaxis: new methods for evaluation and demonstration of a cell-derived chemotactic factor. J. Exp. Med. 137:387.

14. Axelsson, L.-G., G. Nilsson, and B. Bjorksten. 1981. Statistical aspects of cell motility determinations with a modified chemotaxis assembly for multiwell filter assays. J. Immunol. Methods. 46:251.

15. De Lean, A., P. J. Munson, and D. Rodbard. 1978. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose response curves. Am. J. Physiol. 235:E97.

16. Nelson, R. D., P. G. Quie, and R. L. Simmons. 1975. Chemotaxis under agarose: a new and simple method for measuring chemotaxis and spontaneous migration of human polymorphonuclear leukocytes and monocytes. J. Immunol. 115:1650.

17. Munson, P. J. 1981. LIGAND. Biomedical Computing Technology Information Center. Computer Code Collection. (Med.-40) 45.

18. Aitken, R. J., A. Mattei, and S. Irvine. 1986. Paradoxical stimulation of human sperm motility by 2-deoxyadenosine. J. Reprod. Fertil. 78:515.
19. Vijayaraghavan, S., and D. D. Hoskins. 1986. Regulation of bovine sperm motility and cyclic adenosine 3',5'-monophosphate by adenosine and its analogues. Biol. Reprod. 34:468.

20. Teuscher, E., and V. Weidlich. 1985. Adenosine nucleotides, adenosine and adenine as angiogenesis factors. Biomed. Biochim. Acta. 3:493.

21. Nishida, Y., A. Takeuchi, and T. Miyamoto. 1986. Modulation of polymorphonuclear leukocyte function by adenosine analogues. In Purine and Pyrimidine Metabolism in Man. Vol. V. W. L. Nyhan, L. F. Thompson, and R. W. E. Watts, editors. Plenum Press, New York. 487.

22. Garcia-Castro, I., J. M. Mato, G. Vasanthakumar, W. P. Weisman, E. Schiffmann, and P. K. Chiang. 1983. Paradoxical effects of adenosine on neutrophil chemotaxis. J. Biol. Chem. 258:4345.

23. Cronstein, B. N., S. B. Kramer, E. D. Rosenstein, H. M. Korchak, G. Weissmann, and R. Hirschhorn. 1988. Engagement of adenosine receptors raises cAMP alone and in synergy with engagement of the FMLP receptor and inhibits membrane depolarization but does not affect stimulated Ca++ fluxes. Biochem. J. In press.

24. Keller, H. U., A. Naef, and A. Zimmermann. 1984. Effects of colchicine, vinblastine and nocodazole on polarity, motility, chemotaxis and cAMP levels of human polymorphonuclear leukocytes. Exp. Cell Res. 153:173.

25. Naef, A., B. Damereau, and H. U. Keller. 1984. Relationship between the transient cAMP increase, exocytosis from specific and azurophil granules and chemotaxis in neutrophil granulocytes. Agents Actions. 14:65.

26. Simchowitz, L., I. Spilberg, and J. P. Atkinson. 1983. Evidence that the functional responses of human neutrophils occur independently of transient elevations in cyclic AMP levels. J. Cyclic Nucleotide Protein Phosphorylation Res. 9:55.

27. Roch-Arveiller, M., P. Boquet, D. Bradshaw, and J. P. Giroud. 1979. Inhibition by cholera toxin of rat polymorphonuclear leukocyte chemotaxis demonstrated in vitro and in vivo. Infect. Immun. 25:187.

28. Pham Huu, T. 1979. Chemotaxis of human leukocytes. II. Effects of lectins, colchicine, cytochalasin B, cyclic nucleotides and immuno-stimulatory products. Biomedicine (Paris). 30:121.

29. Anderson, R., A. Glover, and A. R. Rabson. 1977. The in vitro effects of histamine and metiamide on neutrophil motility and their relationship to intracellular cyclic nucleotide levels. J. Immunol. 118:1690.

30. Hill, H. R., R. D. Estensen, P. G. Quie, N. A. Hogan, and N. D. Goldberg. 1975. Modulation of human neutrophil chemotactic responses by cyclic 3',5'-guanosine monophosphate and cyclic 3',5'-adenosine monophosphate. Metabolism. 24:447.

31. Pearson, J. D., and J. L. Gordon. 1979. Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides. Nature (Lond.). 281:384.

32. Ager, A., and J. L. Gordon. 1985. Differential effects of hydrogen peroxide on indices of endothelial cell function. J. Exp. Med. 159:592.

33. MacGregor, R. R., H. M. Friedman, E. J. Macarak, and N. A. Kefalides. 1983. Adenine nucleotide release as a measure of endothelial cell injury by PMNs. Clin. Res. 31:2024. (Abstr.)

34. Hirschhorn, R., V. Roegner-Maniscalco, L. Kuritsky, and F. Rosen. 1981. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase deficient patients. J. Clin. Invest. 68:1387.